Filing Flows

Filing Flows › Sempra (SRE) › Guidance & outlook

Sempra (SRE) guidance and outlook

Sempra (SRE) raised its guidance on Nov 5, 2026: EPS $7.41–$8.41 for FY2026; EPS $4.80–$5.30 for FY2026; EPS $5.10–$5.70 for FY2027; Capital expenditures +61% for FY2026. Sempra's 10-Q filed Nov 5, 2026 makes 39 forward-looking statements, 6 of them new and 2 no longer said since the filing before.

Guidance and outlook

Sempra: what its forward-looking statements are about (10-Q filed 2026-11-05)Sempra: what its forward-looking statements are about (10-Q filed 2026-11-05)Other17Capital spending11The economy4Demand4Supply chain1Deals1Legal & regulation1
39 statements; tone +0.03 (−1 all cautious, +1 all confident); 11 hedged.
Sempra: outlook statements against the filing beforeSempra: outlook statements against the filing beforeNew6Updated2Dropped2Confident6Cautious5

Latest guidance

MetricPeriodRangeChange
EPSFY2026$7.41–$8.41raised
EPSFY2026$4.80–$5.30reaffirmed
EPSFY2027$5.10–$5.70reaffirmed
Capital expendituresFY2026+61%reaffirmed

From the earnings release filed Nov 5, 2026 (8-K on EDGAR).

Forward-looking statements, 10-Q filed Nov 5, 2026

Sempra's latest quarter

Sempra, Q3 2026: revenue $3.2B (+1% year over year), operating margin 35.3%, net earnings $883M, operating cash flow $1.6B. The chart follows the revenue to costs, profit and cash.

Questions

Did Sempra raise or lower its guidance?

Sempra (SRE) raised its guidance on Nov 5, 2026: EPS $7.41–$8.41 for FY2026; EPS $4.80–$5.30 for FY2026; EPS $5.10–$5.70 for FY2027; Capital expenditures +61% for FY2026.

What does Sempra expect?

In the three months ended September 30, 2026 compared to the same period in 2025, Sempra’s earnings attributable to NCI increased by $176 million to $231 million primarily due to an increase in SI Partners subsidiaries’ net income driven by unrealized gains in 2026 compared to unrealized losses in 2025 from interest rate swaps related to the PA LNG Phase 1 project, a gain on the sale of Ecogas in August 2026,… For instance, Oncor’s capital expenditures plan from 2026 through 2030 and announced incremental capital expenditure opportunities within this period, that we describe below, include sig

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.